Altria Group (MO) is navigating a challenging landscape, with its stock performance lagging over the past decade due to declining smoking rates and unsuccessful diversification efforts. While the company has historically delivered strong returns, recent investments in Cronos Group and Juul Labs have resulted in significant losses, and a recent acquisition setback involving NJOY devices has compounded its challenges. Despite these issues, Altria has seen a 50% stock increase over the last two years, buoyed by a broader rally in tobacco stocks and promising developments in smoke-free products like its On! oral nicotine pouches.
However, the company’s core cigarette business continues to decline, with a 10% drop in domestic shipments and a reliance on price increases that may not be sustainable. Altria’s target for earnings-per-share growth of 2.5% to 5.5% through 2026, combined with a 6.3% dividend yield, offers some appeal, but the risk remains that without successful new products, the stock could face downward pressure.
Market professionals should closely monitor Altria’s ability to innovate in the smoke-free segment, as its long-term viability hinges on overcoming declining cigarette sales and capturing market share in emerging product categories.
Source: fool.com